<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6522927</article-id><article-id pub-id-type="pmid">31074307</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1611801</article-id><article-id pub-id-type="publisher-id">1611801</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Fibrate-based <italic>N</italic>-acylsulphonamides targeting carbonic anhydrases: synthesis, biochemical evaluation, and docking studies</article-title><alt-title alt-title-type="running-authors">A. Ammazzalorso et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ammazzalorso</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8698-9440</contrib-id><name><surname>Carradori</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1470-7192</contrib-id><name><surname>Angeli</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Akdemir</surname><given-names>Atilla</given-names></name><xref ref-type="aff" rid="AF0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Filippis</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fantacuzzi</surname><given-names>Marialuigia</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giampietro</surname><given-names>Letizia</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maccallini</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amoroso</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu T.</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref><xref ref-type="corresp" rid="AN0002"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmacy, &#x0201c;G. d&#x02019;Annunzio&#x0201d; University of Chieti-Pescara</institution>, Chieti, <country>Italy</country>; </aff><aff id="AF0002"><label>b</label><institution>Laboratorio di Chimica Bioinorganica, Universit&#x000e0; degli Studi di Firenze</institution>, Florence, <country>Italy</country>; </aff><aff id="AF0003"><label>c</label><institution>Department of Pharmacology, Faculty of Pharmacy, Computer-Aided Drug Discovery Laboratory, Bezmialem Vakif University</institution>, Istanbul, <country>Turkey</country>; </aff><aff id="AF0004"><label>d</label><institution>Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Universit&#x000e0; degli Studi di Firenze</institution>, Florence, <country>Italy</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Alessandra Ammazzalorso <email>alessandra.ammazzalorso@unich.it</email><institution>Department of Pharmacy, &#x0201c;G. d&#x02019;Annunzio&#x0201d; University of Chieti-Pescara</institution>, <addr-line>Via dei Vestini 31</addr-line>, 66100Chieti, <country>Italy</country>; </corresp><corresp id="AN0002">Claudiu T. Supuran <email>claudiu.supuran@unifi.it</email><institution>Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Universit&#x000e0; degli Studi di Firenze</institution>, <addr-line>Via U. Schiff 6, Sesto Fiorentino</addr-line>50019, Florence, <country>Italy</country></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>10</day><month>5</month><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage seq="102">1051</fpage><lpage>1061</lpage><history><date date-type="received"><day>06</day><month>3</month><year>2019</year></date><date date-type="rev-recd"><day>17</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ienz-34-1611801.pdf"/><abstract><title>Abstract</title><p>A large library of fibrate-based <italic>N</italic>-acylsulphonamides was designed, synthesised, and fully characterised in order to propose them as zinc binders for the inhibition of human carbonic anhydrase (hCA) enzymatic activity. Synthesised compounds were tested against four hCAs (I, II, IX, and XII) revealing a promising submicromolar inhibitory activity characterised by an isozyme selectivity pattern. Structural modifications explored within this scaffold are: presence of an aryl ring on the sulphonamide, <italic>p</italic>-substitution of this aryl ring, benzothiazole or benzophenone as core nuclei, and an <italic>n</italic>-propyl chain or a geminal dimethyl at C&#x003b1; carbon. Biological results fitted well with molecular modelling analyses, revealing a putative direct interaction with the zinc ion in the active site of hCA I, II and IX. These findings supported the exploration of less investigated secondary sulphonamides as potential hCA inhibitors.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>N-acylsulphonamides</kwd><kwd>carbonic anhydrase</kwd><kwd>PPAR antagonist</kwd><kwd>fibrate derivatives</kwd><kwd>benzothiazole</kwd><kwd>benzophenone</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">FAR funds</named-content></funding-source></award-group><award-group><funding-source><named-content content-type="funder-name">Italian Ministry for Instruction, University and Research</named-content></funding-source></award-group><funding-statement>This work was supported by FAR funds (Italian Ministry for Instruction, University and Research) of Alessandra Ammazzalorso.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="11"/><word-count count="6926"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Sulphonamides and their <italic>N</italic>-acyl derivatives represent common functional groups occurring in natural and synthetic drugs. The different biological activities played by these compounds attracted the attention of medicinal chemists, and a great number of lead compounds of pharmaceutical interest were discovered to date<xref rid="CIT0001" ref-type="bibr"><sup>1&#x02013;3</sup></xref>. Indeed, <italic>N</italic>-acylsulphonamides have been widely used in medicinal chemistry as bioisosteres of carboxylic acids, given the similarity in terms of H-bond properties and acidity<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>. The bioisosteric replacement of carboxylic group with <italic>N</italic>-acylsulphonamide produced novel compounds showing pharmacological activity, sometimes improved with respect to the parent compounds. Paritaprevir (NS3 protease inhibitor)<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>, Venetoclax (Bcl-2 inhibitor)<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>, and Selexipag (prostacyclin receptor agonist)<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref> are <italic>N</italic>-acylsulphonamide drugs recently approved by FDA for the treatment of HCV infection, tumours, and pulmonary arterial hypertension, respectively. A number of <italic>N</italic>-acylsulphonamide derivatives, targeting different enzymes or receptors, have been submitted to clinical or preclinical evaluation: among them, inhibitors of bacterial enzymes<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>, asparagine synthetase inhibitors<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref>, agonists and antagonists of nuclear receptor peroxisome proliferator-activated receptors (PPARs)<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>.</p><p>Historically, secondary sulphonamides represent an important class of drugs targeting carbonic anhydrases (CAs)<xref rid="CIT0013" ref-type="bibr"><sup>13&#x02013;16</sup></xref>. These metalloenzymes, catalysing the CO<sub>2</sub> hydration reaction, are involved in several physiologic functions, also depending on their distribution in different tissues. For these reasons, CA inhibitors present a wide biomedical application, interfering with acid/base regulation, respiration, gluconeogenesis, bone resorption, and tumorigenesis<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. CA inhibitors, containing the sulphonamide moiety, are therapeutically used as diuretic, antiglaucoma, anticancer, and antiobesity drugs. In recent works, <italic>N</italic>-substituted sulphonamides, among other secondary sulphonamides, have been identified as strong human CA I and II inhibitors, showing nanomolar inhibition constants<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>.</p><p>They were characterised by an ionisable moiety as zinc binder directly interacting with the zinc ion in the active site, as demonstrated by X-ray crystallographic studies of human carbonic anhydrase (hCA) II-inhibitor adducts<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. In the attempt to identify novel CA inhibitors, in this work, we describe the screening of <italic>N</italic>-acylsulphonamide derivatives previously synthesised and identified as PPAR antagonists<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. These compounds belong to a library of benzothiazole derivatives of fibrates, known PPAR agonists, obtained by an agonist-antagonist switching programme. The inhibitory properties of these derivatives were evaluated on four selected human CA isozymes (I, II, IX, and XII). These isoforms were selected according to their pharmacological relevance for the discovery of innovative therapeutic approaches against hypoxic cancers (hCA IX and XII) and for their wide distribution in the human body (hCA I and II as off-targets). Starting from previously obtained results, a novel series of benzenesulphonamide derivatives were designed, synthesised, and submitted to CA inhibition assays. Furthermore, molecular modelling studies were carried out to explain the putative interactions between this library of heterocyclic compounds and the active sites of the four isozymes in order to rationalise future synthetic approaches within this scaffold and to further understand the structural requirements to obtain isoform selectivity among the tested CAs.</p></sec><sec id="s0002"><label>2.</label><title>Experimental protocols</title><sec id="s0003"><label>2.1.</label><title>Chemistry</title><p>Melting points were determined with a Buchi Melting Point B&#x02010;450 and were uncorrected. NMR spectra were recorded on a Varian Mercury spectrometer at 300&#x02009;MHz or on a Bruker spectrometer at 400&#x02009;MHz. Proton chemical shifts were referenced to the TMS internal standard. Chemical shifts are reported in parts per million (ppm, &#x003b4; units). Coupling constants are reported in units of Hertz (Hz). Splitting patterns are designed as s, singlet; d, doublet; t, triplet; q, quartet; dd, double doublet; m, multiplet; and b, broad. All commercial chemicals and solvents were reagent grade and were purchased from Sigma-Aldrich (St. Louis, MO); they are used without further purification, unless otherwise specified. Reactions were monitored by thin layer chromatography on silica gel plates (60&#x000a0;F&#x02010;254, Sigma-Aldrich) and the analysis of the plates was carried out using a UV lamp 254/365&#x02009;nm. Flash chromatography was performed on silica gel 60 (Merck, Kenilworth, NJ). Elemental analyses for C, H, and N were recorded on a Perkin-Elmer 240 B microanalyzer obtaining analytical results within &#x000b1;0.4% of the theoretical values for all compounds. The following solvents have been abbreviated: chloroform (CHCl<sub>3</sub>), dichloromethane (DCM), diethyl ether (Et<sub>2</sub>O), dimethyl sulphoxide (DMSO), ethanol (EtOH), methanol (MeOH), and tetrahydrofuran (THF).</p><sec id="s0004"><label>2.1.1.</label><title>General procedure for the synthesis of benzenesulphonamides (19&#x02013;27)</title><p>To a stirred solution of fenofibric acid (1.0&#x02009;mmol) in dry DCM (10&#x02009;mL) at 0&#x02009;&#x000b0;C, 1&#x02010;ethyl&#x02010;3&#x02010;[3&#x02010;dimethylaminopropyl]carbodiimide hydrochloride (EDC, 1.0&#x02009;mmol), and 4&#x02010;dimethylaminopyridine (DMAP, 1.0&#x02009;mmol) were added. After 15&#x02009;min, the selected benzenesulphonamide (1.1&#x02009;mmol) was added to the reaction mixture and the cold water/ice bath was removed. The reaction mixture was allowed to stir 24&#x02009;h, diluted with DCM (10&#x02009;mL), washed with 2N HCl (3&#x02009;&#x000d7;&#x02009;20&#x02009;ml), dried on Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. Crude products were purified by column chromatography.</p><sec id="s0005"><label>2.1.1.1.</label><title>2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-<italic>N</italic>-[(4-methylphenyl)sulfonyl]propanamide (19)</title><p>White solid, 51% yield (silica gel, CHCl<sub>3</sub>/MeOH 98:2); m.p. 185&#x02013;186&#x02009;&#x000b0;C; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>1.44 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 2.29 (s, 3H, C<italic>H<sub>3</sub></italic>Ph), 6.66 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.35 (d, 2H, <italic>J</italic> 8.1&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.51 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.60&#x02013;7.71 (m, 6H, C<italic>H</italic><sub>Ar</sub>), 12.40 (bs, 1H, N<italic>H</italic>, D<sub>2</sub>O exchange);<sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic> 21.3, 24.3, 80.9, 117.9, 128.1, 129.1, 129.9, 130.2, 131.6, 132.1, 136.2, 136.5, 137.5, 144.8, 159.0, 172.9, 193.7. Anal. Calcd. for C<sub>24</sub>H<sub>22</sub>ClNO<sub>5</sub>S: C, 61.08; H, 4.70; N, 2.97. Found: C, 60.93; H, 4.69; N, 2.97.</p></sec><sec id="s0006"><label>2.1.1.2.</label><title>2-[4-(4-Chlorobenzoyl)phenoxy]-<italic>N</italic>-[(4-methoxyphenyl)sulfonyl]-2-methylpropanamide (20)</title><p>White solid, 54% yield (silica gel, DCM/MeOH 98:2); m.p. 188&#x02013;189&#x02009;&#x000b0;C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>1.51 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 3.87 (s, 3H, OC<italic>H<sub>3</sub></italic>), 6.73 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 6.99 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.46 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.62 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.70 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.93 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 8.90 (bs, 1H, N<italic>H</italic>, D<sub>2</sub>O exchange); <sup>13</sup>C NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 24.3, 55.7, 81.5, 114.1, 119.0, 128.6, 129.0, 130.9, 131.2, 131.9, 132.1, 135.8, 138.8, 157.4, 164.1, 171.9. Anal. Calcd. for C<sub>24</sub>H<sub>22</sub>ClNO<sub>6</sub>S: C, 59.07; H, 4.54; N, 2.87. Found: C, 59.19; H, 4.53; N, 2.88.</p></sec><sec id="s0007"><label>2.1.1.3.</label><title>2-[4&#x02013;(4-Chlorobenzoyl)phenoxy]-<italic>N</italic>-[(4-chlorophenyl)sulfonyl]-2-methylpropanamide (21)</title><p>White solid, 69% yield (silica gel, DCM/MeOH 98:2); m.p. 204&#x02013;205&#x02009;&#x000b0;C (dec); <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>1.44 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 6.73 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.46&#x02013;7.69 (m, 9H, C<italic>H</italic><sub>Ar</sub>, and N<italic>H</italic>, D<sub>2</sub>O exchange), 7.78 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>); <sup>13&#x02009;</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic> 24.8, 81.3, 117.8, 128.0, 129.0, 129.3, 129.5, 129.8, 129.9, 131.5, 132.0, 136.7, 137.4, 159.5, 174.0, 193.6. Anal. Calcd. for C<sub>23</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>5</sub>S: C, 56.11; H, 3.89; N, 2.84. Found: C, 56.24; H, 3.88; N, 2.84.</p></sec><sec id="s0008"><label>2.1.1.4.</label><title>2-[4&#x02013;(4-Chlorobenzoyl)phenoxy]-2-methyl-<italic>N</italic>-[(4-nitrophenyl)sulfonyl]propanamide (22)</title><p>White solid, 56% yield (silica gel, DCM/MeOH 98:2); m.p. 196&#x02013;198&#x02009;&#x000b0;C; <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>1.45 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 6.71 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.54 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.61 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.68 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 8.03 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 8.34 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>); <sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>24.8, 81.3, 117.8, 124.5, 129.0, 129.4, 130.0, 131.5, 132.0, 136.6, 137.5, 150.1, 159.4, 174.3, 193.6. Anal. Calcd. for C<sub>23</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>7</sub>S: C, 54.93; H, 3.81; N, 5.57. Found: C, 55.07; H, 3.79; N, 5.56.</p></sec><sec id="s0009"><label>2.1.1.5.</label><title><italic>N</italic>-{[4-(acetylamino)phenyl]sulfonyl}-2-[4&#x02013;(4-chlorobenzoyl)phenoxy]-2-methylpropanamide (23)</title><p>White solid, 53% yield (silica gel, DCM/MeOH 98:2); m.p. 226&#x02013;228&#x02009;&#x000b0;C; <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>1.44 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 2.03 (s, 3H, C<italic>H<sub>3</sub></italic>), 6.69 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.52&#x02013;7.78 (m, 10H, C<italic>H</italic><sub>Ar</sub>), 10.37 (bs, 1H, N<italic>H</italic>SO<sub>2</sub>, D<sub>2</sub>O exchange), 12.38 (bs, 1H, N<italic>H</italic>Ph, D<sub>2</sub>O exchange); <sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>24.3, 24.5, 80.9, 118.1, 118.6, 129.0, 129.4, 130.4, 131.6, 132.0, 136.5, 137.5, 144.3, 159.0, 169.4, 172.7, 173.4, 193.5. Anal. Calcd. for C<sub>25</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>6</sub>S: C, 58.31; H, 4.50; N, 5.44. Found: C, 58.44; H, 4.50; N, 5.43.</p></sec><sec id="s0010"><label>2.1.1.6.</label><title><italic>N</italic>-{4-[({2-[4&#x02013;(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl}amino)sulfonyl]phenyl} benzamide (24)</title><p>White solid, 51% yield (silica gel, CHCl<sub>3</sub>/MeOH 98:2); m.p. 232&#x02013;234&#x02009;&#x000b0;C; <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>1.46 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 6.71 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.51&#x02013;7.68 (m, 9H, C<italic>H</italic><sub>Ar</sub>), 7.82 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.84&#x02013;7.98 (m, 4H, C<italic>H</italic><sub>Ar</sub>), 10.64 (bs, 1H, N<italic>H</italic>SO<sub>2</sub>, D<sub>2</sub>O exchange), 12.45 (bs, 1H, N<italic>H</italic>Ph, D<sub>2</sub>O exchange); <sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>24.4, 81.0, 118.2, 120.1, 126.9, 128.3, 128.9, 129.3, 130.5, 131.6, 132.4, 134.7, 136.5, 137.6, 139.2, 142.6, 144.4, 159.0, 166.5, 172.8, 193.6. Anal. Calcd. for C<sub>30</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>6</sub>S: C, 62.44; H, 4.37; N, 4.85. Found: C, 62.35; H, 4.36; N, 4.86.</p></sec><sec id="s0011"><label>2.1.1.7.</label><title>2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-<italic>N</italic>-({4-[(phenylacetyl)amino]phenyl}sulphonyl) propanamide (25)</title><p>White solid, 47% yield (silica gel, DCM/MeOH 98:2); m.p. 170&#x02013;172&#x02009;&#x000b0;C; <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>1.43 (s, 6H, C(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 3.64 (s, 2H, C<italic>H<sub>2</sub></italic>), 6.72 (d, 2H, <italic>J</italic> 8.1&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.19&#x02013;7.30 (m, 5H, C<italic>H</italic><sub>Ar</sub>), 7.55&#x02013;7.76 (m, 10H, C<italic>H</italic><sub>Ar</sub>), 10.63 (bs, 1H, N<italic>H</italic>SO<sub>2</sub>, D<sub>2</sub>O exchange); <sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x003b4;</italic>24.4, 43.7, 81.0, 118.3, 118.9, 127.1, 128.8, 129.1, 129.5, 129.6, 131.6, 132.0, 135.8, 136.5, 144.2, 159.0, 170.3, 172.8, 193.6. Anal. Calcd. for C<sub>31</sub>H<sub>27</sub>ClN<sub>2</sub>O<sub>6</sub>S: C, 62.99; H, 4.60; N, 4.74. Found: C, 62.89; H, 4.61; N, 4.75.</p></sec><sec id="s0012"><label>2.1.1.8.</label><title>2-(4-Benzoylphenoxy)-<italic>N</italic>-(phenylsulphonyl)acetamide (26)</title><p>White solid, 59% yield (silica gel, DCM); m.p. 61&#x02013;62&#x02009;&#x000b0;C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>4.55 (s, 2H, C<italic>H<sub>2</sub></italic>), 6.95 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.45&#x02013;7.83 (m, 5H, C<italic>H</italic><sub>Ar</sub>), 7.66&#x02013;7.83 (m, 5H, C<italic>H</italic><sub>Ar</sub>), 8.10 (d, 2H, <italic>J</italic> 7.5&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 9.06 (bs, 1H, N<italic>H</italic>, D<sub>2</sub>O exchange); <sup>13</sup>C NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>77.2, 114.4, 126.4, 128.3, 129.0, 129.1, 129.8, 132.3, 132.6, 132.8, 137.6, 142.0, 159.7, 195.2. Anal. Calcd. for C<sub>21</sub>H<sub>17</sub>NO<sub>5</sub>S: C, 63.79; H, 4.33; N, 3.54. Found: C, 64.02; H, 4.32; N, 3.53.</p></sec><sec id="s0013"><label>2.1.1.9.</label><title>2-(4-Benzoylphenoxy)-<italic>N</italic>-(phenylsulphonyl)pentanamide (27)</title><p>White solid, 49% yield (silica gel, DCM); m.p. 140&#x02013;142&#x02009;&#x000b0;C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>0.87 (t, 3H, <italic>J</italic> 6.9&#x02009;Hz, C<italic>H<sub>3</sub></italic>), 1.36&#x02013;1.43 (m, 2H, C<italic>H<sub>2</sub></italic>), 1.82&#x02013;1.91 (m, 2H, C<italic>H<sub>2</sub></italic>), 4.58 (t, 1H, <italic>J</italic> 6.0&#x02009;Hz, C<italic>H</italic>), 6.83 (d, 2H, <italic>J</italic> 9.0&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.46&#x02013;7.65 (m, 6H, C<italic>H</italic><sub>Ar</sub>), 7.71&#x02013;7.76 (m, 4H, C<italic>H</italic><sub>Ar</sub>), 7.95 (d, 2H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 8.81 (bs, 1H, N<italic>H</italic>, D<sub>2</sub>O exchange); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>13.5, 17.8, 34.1, 78.6, 114.7, 126.4, 128.3, 129.0, 129.8, 132.0, 132.3, 132.6, 134.2, 137.6, 137.9, 159.6, 169.3, 195.2. Anal. Calcd. for C<sub>24</sub>H<sub>23</sub>NO<sub>5</sub>S: C, 65.89; H, 5.30; N, 3.20. Found: C, 65.91; H, 5.29; N, 3.21.</p></sec></sec><sec id="s0014"><label>2.1.2.</label><title>General procedure for the synthesis of esters (29 and 31)</title><p>A solution of sodium (2.5&#x02009;mmol) in absolute EtOH (10&#x02009;ml) was added to 4-hydroxybenzophenone (2.5&#x02009;mmol), dissolved in absolute EtOH (10&#x02009;ml), at room temperature, and under nitrogen atmosphere. Ethyl 2-bromoacetate (or ethyl 2-bromovalerate) (2.5&#x02009;mmol) in absolute EtOH (5&#x02009;ml), was added to the mixture, and the resulting solution was refluxed for 20&#x02009;h. After evaporation of solvent under reduced pressure, the residue was poured into water (20&#x02009;ml) and extracted with Et<sub>2</sub>O (3&#x02009;&#x000d7;&#x02009;20&#x02009;mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure.</p><sec id="s0015"><label>2.1.2.1.</label><title>Ethyl (4-benzoylphenoxy)acetate (29)</title><p>White solid, 63% yield. Characterisation data were in agreement with those reported in the literature<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p></sec><sec id="s0016"><label>2.1.2.2.</label><title>Ethyl 2&#x02013;(4-benzoylphenoxy)pentanoate (31)</title><p>Pale yellow oil, 69% yield (silica gel, DCM); <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>0.98 (t, 3H, <italic>J</italic> 6.9&#x02009;Hz, C<italic>H<sub>3</sub></italic>), 1.25 (t, 3H, <italic>J</italic> 6.9&#x02009;Hz, C<italic>H<sub>3</sub></italic>), 1.49&#x02013;1.63 (m, 2H, C<italic>H<sub>2</sub></italic>), 1.83&#x02013;2.08 (m, 2H, C<italic>H<sub>2</sub></italic>), 4.23 (q, 2H, <italic>J</italic> 7.2&#x02009;Hz, OC<italic>H<sub>2</sub></italic>), 4.70 (dd, 1H, <italic>J</italic> 7.8&#x02009;Hz, <italic>J</italic> 7.5&#x02009;Hz, C<italic>H</italic>), 6.92 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.43&#x02013;7.48 (m, 2H, C<italic>H</italic><sub>Ar</sub>), 7.52&#x02013;7.59 (m, 1H, C<italic>H</italic><sub>Ar</sub>), 7.75 (d, 2H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.79 (d, 2H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>); <sup>13</sup>C NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 13.6, 14.1, 18.5, 34.6, 61.4, 76.2, 114.4, 128.2, 129.7, 130.7, 131.9, 132.5, 138.0, 161.4, 171.2, 195.5. Anal. Calcd. for C<sub>20</sub>H<sub>22</sub>O<sub>4</sub>: C, 73.60; H, 6.79; Found: C, 73.52; H, 6.81.</p></sec></sec><sec id="s0017"><label>2.1.3.</label><title>General procedure for the synthesis of acids (30 and 32)</title><p>2N NaOH (12.5&#x02009;mmol) was added to esters <bold>29</bold> and <bold>31</bold> (1.5&#x02009;mmol) in THF (10&#x02009;ml) and the mixture was stirred at r.t. overnight. THF was removed under reduced pressure; the solution was acidified by 4N HCl, obtaining a precipitate that was collected by filtration under vacuum.</p><sec id="s0018"><label>2.1.3.1.</label><title>(4-Benzoylphenoxy)acetic acid (30)</title><p>White solid, 72% yield. Characterisation data were in agreement with those reported in the literature<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p></sec><sec id="s0019"><label>2.1.3.2.</label><title>2-(4-Benzoylphenoxy)pentanoic acid (32)</title><p>White solid, 99% yield; m.p. 75&#x02013;77&#x02009;&#x000b0;C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic>0.98 (t, 3H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H<sub>3</sub></italic>), 1.50&#x02013;1.63 (m, 2H, C<italic>H<sub>2</sub></italic>), 1.96&#x02013;2.05 (m, 2H, C<italic>H<sub>2</sub></italic>), 4.75 (dd, 1H, <italic>J</italic> 7.8&#x02009;Hz, <italic>J</italic> 7.8&#x02009;Hz, C<italic>H</italic>), 6.93 (d, 2H, <italic>J</italic> 8.7&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.43&#x02013;7.48 (m, 2H, C<italic>H</italic><sub>Ar</sub>), 7.53&#x02013;7.59 (m, 1H, C<italic>H</italic><sub>Ar</sub>), 7.74 (d, 2H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>), 7.81 (d, 2H, <italic>J</italic> 7.2&#x02009;Hz, C<italic>H</italic><sub>Ar</sub>); <sup>13</sup>C NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 13.6, 18.5, 34.5, 75.6, 114.4, 128.2, 129.8, 130.9, 132.1, 132.6, 137.9, 161.2, 175.9, 195.7. Anal. Calcd. for C<sub>18</sub>H<sub>18</sub>O<sub>4</sub>: C, 72.47; H, 6.08; Found: C, 72.51; H, 6.07.</p></sec></sec></sec><sec id="s0020"><label>2.2.</label><title>CA inhibition assays</title><p>An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO<sub>2</sub> hydration activity. Phenol red (0.2&#x02009;mM) has been used as indicator, working at the absorbance maximum of 557&#x02009;nm, with 20&#x02009;mM Hepes (pH 7.5, for &#x003b1;-CAs) as buffer, and 20&#x02009;mM NaClO<sub>4</sub> (for maintaining constant the ionic strength), following the initial rates of the CA-catalysed CO<sub>2</sub> hydration reaction for a period of 10&#x02013;100&#x02009;s. The CO<sub>2</sub> concentrations ranged from 1.7 to 17&#x02009;mM for the determination of the kinetic parameters and inhibition constants. In particular, CO<sub>2</sub> was bubbled in distilled deionised water for 30&#x02009;min till saturation. A CO<sub>2</sub> kit (Sigma, Milan, Italy) was used to measure the concentration in serially diluted solutions from the saturated one at the same temperature. For each inhibitor at least six traces of the initial 5&#x02013;10% of the reaction have been used for determining the initial velocity. The uncatalysed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (1&#x000a0;&#x000b5;M) were prepared in distilled&#x02013;deionised water and dilutions up to 0.1&#x02009;nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15&#x02009;min at room temperature prior to assay, in order to allow for the formation of the E&#x02013;I complex or for the eventual active site mediated hydrolysis of the inhibitor. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng&#x02013;Prusoff equation and represent the average from at least three different determinations. All recombinant CA isoforms were obtained in-house as previously reported<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p></sec><sec id="s0021"><label>2.3.</label><title>Molecular modelling studies</title><p>Crystal structures of hCA I (pdb: 3lxe, 1.9&#x000a0;&#x000c5;, in complex with topiramate), hCA II (pdb: 4e3d, 1.6&#x000a0;&#x000c5;, in complex with 2,5-dihydroxybenzoic acid), hCA IX (pdb: 3iai, 2.2&#x000a0;&#x000c5;, in complex with acetazolamide [AAZ]) and XII (pdb: 1jd0, 1.5&#x000a0;&#x000c5;, in complex with AAZ) were obtained from the Brookhaven Protein Data Bank. All ligands (AAZ, topiramate and 2,5-dihydroxybenzoic acid) and the zinc-bound water molecule of the hCA II structure were retained and all other non-protein atoms were deleted. Chain A was retained if more than one protein structure was present in the crystal structure. Hydrogen atoms were added with the &#x0201c;protonate 3&#x02009;D&#x0201d; tool and subsequently a steepest-descent energy minimisation was performed using the AMBER14:EHT force field (MOE software package, version 2018.0101, chemical computing group, Inc., Montreal, Canada)<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. The four protein structures were superposed on the backbone atoms of hCA I (C&#x003b1; atoms, RMSD: 1.395&#x000a0;&#x000c5;, for 236 residues). The coordinates of the hCA II zinc-bound water molecule were copied into the other hCA structures.</p><p>The molecular structures of the ligands were prepared with the MOE software package. All stereoisomers were generated. Subsequently, the ligand structures were energy minimised (MMFF94x force field) and the ligands were saved as multi-mol2 files.</p><p>Docking calculations were performed with the GOLD software package version 5.6.1 (CCDC, Cambridge, UK) using the ChemScore scoring function (25 genetic algorithm runs per ligand) and default settings. The binding pocket was defined as within 14&#x000a0;&#x000c5; around a centroid (x: &#x02212;18.899; Y: 36.167; z: 45.640; corresponds to the AAZ O<sub>3</sub> atom of the hCA IX structure after superposition upon the hCA I structure). Dockings into the active site were performed either with or without a zinc-bound water molecule (obtained from hCA II structure 4e3d)<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>.</p></sec></sec><sec id="s0022"><label>3.</label><title>Results and discussion</title><sec id="s0023"><label>3.1.</label><title>Synthetic approach and <italic>in vitro</italic> CA inhibition studies</title><p>A wide group of benzothiazole compounds, bearing an <italic>N</italic>-acylsulphonamide portion, have been firstly synthesised by our research group and tested as PPAR antagonists. Some of them were also studied for assessing antitumor effects, mainly in cancer models overexpressing PPAR&#x003b1;<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>. We decided to evaluate their inhibitory effect on four selected human CA isoenzymes (I, II, IX, and XII) and AAZ was used as reference compound. A preliminary screening of compounds <bold>1&#x02013;7</bold>, methane and benzenesulphonamide derivatives, was carried out, and the results are reported in <xref rid="t0001" ref-type="table">Table 1</xref>. The greater affinities showed by benzenesulphonamide derivatives prompted us to further explore benzenesulphonamide derivatives such as <italic>p</italic>-substitutions on the aromatic ring (<bold>8&#x02013;14</bold>). In addition, we also tested compounds <bold>15&#x02013;18</bold>, previously synthesised starting from the parent compounds clofibrate, gemfibrozil, bezafibrate, and fenofibrate<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Inhibitory activity of derivatives <bold>1&#x02013;18</bold> and reference compound acetazolamide (<bold>AAZ</bold>) against four selected hCA isoforms (I, II, IX, and XII) by stopped-flow CO<sub>2</sub> hydrase assay<xref rid="CIT0031" ref-type="bibr"><sup>31&#x02013;35</sup></xref>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><col width="1*"/><tbody valign="top"><tr><td align="left"><inline-graphic xlink:href="IENZ_A_1611801_ILG0001.gif"/><inline-graphic xlink:href="IENZ_A_1611801_ILG0002.gif"/></td></tr></tbody></table></table-wrap><p>The three methanesulphonamide derivatives (compounds <bold>2</bold>, <bold>4</bold>, <bold>6</bold>) showed no activity against CA except for compound <bold>2</bold> which had a slight activity against hCA XII (<italic>K</italic><sub>i&#x000a0;</sub>= 61.0&#x02009;&#x003bc;M), whereas corresponding benzenesulphonamides (<bold>1</bold>, <bold>3</bold>, <bold>5</bold>) moderately inhibited CA I, II, and IX, with a slight preference for CA II. Compounds <bold>1&#x02013;4</bold> and <bold>6&#x02013;7</bold>, bearing an alkylic chain on C&#x003b1; (adjacent to carbonyl group), produced an improved CA inhibition compared to phenyl derivative <bold>5</bold>.</p><p>The series of compounds <bold>8</bold>&#x02013;<bold>14</bold> includes <italic>p</italic>-substituted benzenesulphonamides, obtained starting from compound <bold>7</bold>. The best inhibition profiles against CA were found for <italic>p</italic>-methoxy derivative <bold>9</bold> and <italic>p</italic>-chloro derivative <bold>10</bold>. They produced a selective inhibition with submicromolar <italic>K</italic><sub>i</sub> values against hCA IX and hCA II respectively. The insertion of methyl (<bold>8</bold>), nitro (<bold>11</bold>), acetylamino (<bold>12</bold>), benzoylamino (<bold>13</bold>) and phenylacetylamino (<bold>14</bold>) groups did not improve their inhibition properties.</p><p>Benzenesulphonamides <bold>15</bold>&#x02013;<bold>18</bold>, obtained by their carboxylic precursors, were all inactive against CA XII. Compounds <bold>15</bold> and <bold>16</bold> (clofibrate and gemfibrozil derivatives) were completely inactive against all tested isoenzymes, whereas <bold>17</bold> and <bold>18</bold> showed a moderate inhibition against CA I, II and IX. The best inhibition values were found for <bold>18</bold> (fenofibrate derivative), that showed submicromolar <italic>K</italic><sub>i</sub> inhibition against I and IX isoenzymes.</p><p>According to the above reported results, we selected fenofibrate derivative <bold>18</bold> as a novel lead compound to develop novel chemical derivatives, by adding substituents in <italic>para</italic> position to the benzenesulphonamide moiety (<xref ref-type="fig" rid="F0001">Figure 1</xref>) such as methyl, methoxy, chlorine, nitro, acetylamino, benzoylamino, and phenylacetylamino groups. Compounds <bold>19&#x02013;25</bold> were easily synthesised by reacting fenofibric acid, obtained from hydrolysis of fenofibrate, with <italic>p</italic>-substituted benzenesulphonamides, in the presence of 1-ethyl-3&#x02013;(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP), in dry dichloromethane and under nitrogen atmosphere (<xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>From lead compound <bold>18</bold> to novel benzenesulphonimides <bold>19&#x02013;27</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1611801_F0001_B"/></fig><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Reagents and conditions: (a) <italic>p</italic>-substituted benzenesulphonamide, EDC, DMAP, dry dichloromethane, 0&#x02009;&#x000b0;C-r.t., 24&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1611801_SCH0001_B"/></fig><p>With the aim to evaluate the effect of steric hindrance on C&#x003b1;, we planned the synthesis of <bold>26</bold> and <bold>27</bold> (<xref ref-type="fig" rid="F0001">Figure 1</xref>), where the C&#x003b1; was unsubstituted or substituted with an <italic>n</italic>-propylic chain; both derivatives are lacking of chlorine substitution on benzophenone ring.</p><p>Finally, products <bold>26</bold> and <bold>27</bold> were synthesised as depicted in <xref ref-type="scheme" rid="SCH0002 SCH0003">Schemes 2&#x02013;3</xref>. Esters <bold>29</bold> and <bold>31</bold> were obtained by nucleophilic displacement of proper ethyl 2-bromoalkanoates by 4-hydroxybenzophenone; hydrolysis by 2N NaOH afforded acids <bold>30</bold> and <bold>32</bold>, that were coupled with benzenesulphonamide as previously described.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Reagents and conditions: (a) ethyl 2-bromoacetate, sodium, absolute ethanol, reflux, 20&#x02009;h; (b) 2N NaOH, THF, r.t., 24&#x02009;h; (c) benzenesulphonamide, EDC, DMAP, dry dichloromethane, 0&#x02009;&#x000b0;C-r.t., 24&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1611801_SCH0002_B"/></fig><fig id="SCH0003" orientation="portrait" position="float"><label>Scheme 3.</label><caption><p>Reagents and conditions: (a) ethyl 2-bromovalerate, sodium, absolute ethanol, reflux, 20&#x02009;h; (b) 2N NaOH, THF, r.t., 24&#x02009;h; (c) benzenesulphonamide, EDC, DMAP, dry dichloromethane, 0&#x02009;&#x000b0;C-r.t., 24&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1611801_SCH0003_B"/></fig><p>Compounds <bold>19&#x02013;27</bold> were also screened against CA I, II, IX, and XII to derive robust SAR within this scaffold: results are shown in <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Inhibitory activity of derivatives <bold>19&#x02013;27</bold> and reference compound acetazolamide (AAZ) against four selected hCA isoforms (hCA I, II, IX, and XII) by stopped-flow CO<sub>2</sub> hydrase assay<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><col width="1*"/><tbody valign="top"><tr><td align="left"><inline-graphic xlink:href="IENZ_A_1611801_ILG0003.gif"/></td></tr></tbody></table></table-wrap><p>Overall, the <italic>p</italic>-substitution of aromatic ring with respect to parent derivative <bold>18</bold> did not improve hCA inhibition, except for compounds <bold>22</bold> and <bold>24</bold>, showing both a marked inhibition of hCA II (<italic>K</italic><sub>i&#x000a0;</sub>=16 and 77&#x02009;nM, respectively), and a good selectivity <italic>versus</italic> this isoform. The presence of an acetylamino group was detrimental for hCA inhibition (<bold>23</bold>), whereas the introduction of an additional aromatic ring (<bold>24</bold>) produced a marked effect on both hCA I and hCA II. The further elongation of the substituent (<bold>25</bold>) decreased the inhibitory effect. Compounds <bold>26</bold> and <bold>27</bold>, lacking of the chlorine atom on benzophenone structure and showing a different steric hindrance on C&#x003b1;, did not induce a sensible inhibition of tested isoenzymes.</p></sec><sec id="s0024"><label>3.2.</label><title>Molecular modelling studies</title><sec id="s0025"><label>3.2.1.</label><title>Docking studies into the active site of hCA I</title><p>The ligands were docked into the active site of hCA I with and without a zinc-bound water molecule. This water molecule was obtained from the hCA II structure (pdb: 4e3d) as described in the Materials and Methods section. Compounds <bold>3</bold>, <bold>18</bold>, <bold>21,</bold> and <bold>24</bold> show lower <italic>K</italic><sub>i</sub> values than 10&#x02009;&#x003bc;M (<xref rid="t0001" ref-type="table">Tables 1</xref> and <xref rid="t0002" ref-type="table">2</xref>). Two different poses have been identified in which the ligands can directly interact with the active site zinc ion. In the first pose, the carbonyl group located between the two phenyl moieties forms an interaction with the active site zinc ion (<xref ref-type="fig" rid="F0002">Figure 2(A)</xref>). The two phenyl groups form hydrophobic interactions with His64, Ala121, Val143, Leu198, His200, and Val207. A second hydrogen bond is formed between the other carbonyl atom of the ligand and the side chain of His67. The terminal unsubstituted phenyl group forms a hydrophobic interaction with the side chain of Val62. In addition, hydrogen atoms of His64 and Leu198 point towards the centroids of the phenyl rings resulting in aromatic-H bonds. The sulphonamide group is solvent exposed. This pose is observed for many compounds, including compounds <bold>18</bold> and <bold>24</bold>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>(A) The docked pose of compound <bold>18</bold> (turquoise), (B) compound <bold>21</bold> (purple) and (C) compound <bold>1</bold> (<italic>R</italic>-isomer; green) in the active site of hCA I (pdb: 3lxe). Hydrogen bonds and interactions to the active site zinc ion are indicated in red dashed lines. Aromatic system &#x02013; H bonds are indicated in yellow dashed lines.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1611801_F0002_C"/></fig><p>In the second docked pose, the sulphonamide moiety is located close the active site zinc ion (<xref ref-type="fig" rid="F0002">Figure 2(B)</xref>). One of the sulphonamide oxygen atoms forms an interaction with the zinc ion, while the other oxygen atom forms a hydrogen bond with the backbone of Thr199. The chlorine-substituted phenyl group forms hydrophobic interactions with Ala121, Leu141, Val143, and Leu198. One of the ligand&#x02019;s hydrogen atoms points towards the centre of His94 to form aromatic-H bonds. No additional hydrogen bonds are observed between the ligand and the enzyme, however, the amide bond and the carbonyl group of the ligand are solvent accessible and may form interaction with water. This pose is observed for many compounds, including compounds <bold>3</bold>, <bold>18,</bold> and <bold>21</bold>.</p><p>Docked poses have been identified in which the ligands directly interact with the zinc-bound water molecule. For example, the <italic>R</italic> isomer of compound <bold>1</bold> forms a hydrogen bond with the water molecule through its sulphonamide oxygen atom (<xref ref-type="fig" rid="F0002">Figure 2(C)</xref>). The carbonyl group of the ligand forms a hydrogen bond with the side chain of Gln92. A third hydrogen bond is formed between the ligand and the side chain of Trp5. The propyl group of the ligand is located in a hydrophobic pocket formed by Val62, His64, His67, and His200. The phenyl group of the ligand forms hydrophobic interactions with Phe91, Leu131, Leu141, and Leu198. Interestingly, similar docked poses have not been obtained for the <italic>S</italic> isomer of compound <bold>1</bold>. Similar observations have been made for the other compounds in which some isoforms may bind to one stereoisomer but not to the other.</p></sec><sec id="s0026"><label>3.2.2.</label><title>Docking studies into the active site of hCA II</title><p>The docked pose of compound <bold>22</bold> (<italic>K</italic><sub>i&#x000a0;</sub>=16&#x02009;nM) suggests that the nitro group could be located near the zinc ion (<xref ref-type="fig" rid="F0003">Figure 3(A)</xref>). The partially negatively charged oxygen atoms of the nitro group may form a hydrogen bond with the backbone of Thr199 and electrostatic interactions with the zinc ion. One of the sulphonamide oxygen atoms forms a hydrogen bond with the side chain of Gln92, while the other oxygen atom is water-accessible. The ligand amide group forms a hydrogen bond with the side chain of Asn67 and the chlorine substituent is close enough to the side chain of Lys170 for electrostatic interactions (distance = 4.5&#x000a0;&#x000c5;). Hydrophobic interactions are formed mainly with Leu198. All hydrogen bond donors and acceptors of the ligand that do not interact with the active site are water-accessible.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>The docked pose of (A) compound <bold>22</bold> (turquoise) and (B) compound <bold>18</bold> (purple) in the active site of hCA II (pdb: 4e3d). Hydrogen bonds and interactions to the active site zinc ion are indicated in red dashed lines. Aromatic system &#x02013; H bonds are indicated in yellow dashed lines.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1611801_F0003_C"/></fig><p>The docked pose of compound <bold>18</bold> (<italic>K</italic><sub>i&#x000a0;</sub>= 1.3&#x02009;&#x003bc;M) indicates that the sulphonamide moiety of the ligand is located near the zinc ion (<xref ref-type="fig" rid="F0003">Figure 3(B)</xref>). One of the sulphonamide oxygen forms a direct interaction with the zinc ion, while the other oxygen atom may form hydrogen bonds with Leu198 (backbone) and/or Thr200 (backbone and side chain). One of the side chain hydrogen atoms of Asn67 points towards the centroid of the ligand phenyl group, which could lead to aromatic-H interactions. The chlorine substituent may form electrostatic interactions with Lys170 (distance =5.4&#x000a0;&#x000c5;).</p><p>Many docked poses of the other ligands show a similar position for the sulphonamide group as obtained for compound <bold>18</bold>.</p></sec><sec id="s0027"><label>3.2.3.</label><title>Docking studies into the active site of hCA IX</title><p>The docked pose for compound <bold>18</bold> (<italic>K</italic><sub>i</sub>&#x02009;=&#x02009;0.44&#x02009;&#x003bc;M) indicates that the sulphonamide may be located close to the zinc ion, enabling one oxygen to form an interaction with the zinc ion (tetrahedral orientation around zinc) and the other oxygen atom to form hydrogen bonds with Thr200 (<xref ref-type="fig" rid="F0004">Figure 4(A)</xref>). The carbonyl group adjacent to the sulphonamide moiety is located close to the zinc ion and interaction may occur, resulting in a distorted trigonal bipyramidal orientation around zinc. The terminal phenyl moiety forms hydrophobic interactions with Val121, Val143, and Leu198. The central phenyl group forms hydrophobic interactions with Trp5, while the substituted phenyl group forms hydrophobic interactions with Pro202. A similar docked pose as described for compound <bold>18</bold> or other docked poses in which the ligand directly interacts with the zinc ion are not observed for most of the compounds.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>The docked pose of (A) compound <bold>18</bold> (purple) and (B) alternative docked pose of compound <bold>18</bold> (purple) in the active site of hCA IX (pdb: 3iai). Hydrogen bonds and interactions to the active site zinc ion are indicated in red dashed lines. Aromatic system &#x02013; H bonds are indicated as yellow dashed lines.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1611801_F0004_C"/></fig><p>An alternative docked pose has been obtained for compound <bold>18</bold> in which it interacts with the zinc-bound water molecule <italic>via</italic> one of its sulphonamide oxygen atoms (<xref ref-type="fig" rid="F0004">Figure 4(B)</xref>). The other oxygen atom forms a hydrogen bond to the side chain of Gln92. A second hydrogen bond is formed with the side chain of Trp5. The ligand phenyl group forms hydrophobic interactions with Pro202, while the two methyl groups are located in a hydrophobic cavity formed by Val131, Leu135, Leu141, and Leu198.</p></sec><sec id="s0028"><label>3.2.4.</label><title>Docking studies into the active site of hCA XII</title><p>No docking poses have been obtained in which the ligands interact directly with the zinc ion or the zinc-bound water molecule.</p></sec></sec></sec><sec id="s0029"><label>4.</label><title>Conclusions</title><p>This library of fibrate-based <italic>N</italic>-acylsulphonamides supported the exploration of other zinc binders for the inhibition of human CAs with respect to the widely studied primary sulphonamides. These secondary sulphonamides maintained the possibility to interact with the zinc ion through several binding modes. As also reported in previous crystallographic studies, they present a reduced submicromolar inhibitory activity, but they gained an interesting isoform selectivity against the four tested hCAs. With the support of molecular modelling studies, we assessed the structural requirements within this scaffold to further improve the biological activity such as the presence of an aryl ring on the sulphonamide, <italic>p</italic>-substitution of this aryl ring, benzothiazole or benzophenone as tailing moieties, and an <italic>n</italic>-propyl chain or a geminal dimethyl at C&#x003b1; carbon.</p></sec></body><back><sec id="s0030"><title>Disclosure statement</title><p>The authors state no conflict of interest and they have received no payment in preparation of this manuscript.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal" id="CIT0001-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source><year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0001-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Carta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name></person-group>
<article-title>Sulfonamides and their isosters as carbonic anhydrase inhibitors</article-title>. <source>Future Med Chem</source><year>2014</year>;<volume>6</volume>:<fpage>1149</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25078135</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Mushtaq</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Naz</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Sulfonamides as potential bioactive scaffolds</article-title>. <source>Curr Org Chem</source><year>2018</year>;<volume>22</volume>:<fpage>818</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Filippis</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Giampietro</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Amoroso</surname><given-names>R</given-names></name></person-group>
<article-title><italic>N</italic>-acylsulfonamides: synthetic routes and biological potential in medicinal chemistry</article-title>. <source>Chem Biol Drug Des</source><year>2017</year>;<volume>90</volume>:<fpage>1094</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">28632928</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meanwell</surname><given-names>NA</given-names></name></person-group>
<article-title>Synopsis of some recent tactical application of bioisosteres in drug design</article-title>. <source>J Med Chem</source><year>2011</year>;<volume>54</volume>:<fpage>2529</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">21413808</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilot-Matias</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tripathi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title><italic>In vitro</italic> and <italic>in vivo</italic> antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450</article-title>. <source>Antimicrob Agents Chemother</source><year>2015</year>;<volume>59</volume>:<fpage>988</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">25451053</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souers</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Leverson</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Boghaert</surname><given-names>ER</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets</article-title>. <source>Nat Med</source><year>2013</year>;<volume>19</volume>:<fpage>202</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23291630</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kuwano</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>An oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</article-title>. <source>J Med Chem</source><year>2015</year>;<volume>58</volume>:<fpage>7128</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">26291199</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winton</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Aldrich</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kiessling</surname><given-names>LL</given-names></name></person-group>
<article-title>Carboxylate surrogates enhance the antimycobacterial activity of UDP-galactopyranose mutase probes</article-title>. <source>ACS Infect Dis</source><year>2016</year>;<volume>2</volume>:<fpage>538</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27626294</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kale</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Raichurkar</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Design and synthesis of triazolopyrimidine acylsulfonamides as novel anti-mycobacterial leads acting through inhibition of acetohydroxyacid synthase</article-title>. <source>Bioorg Med Chem Lett</source><year>2014</year>;<volume>24</volume>:<fpage>2222</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">24703230</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koroniak</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ciustea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gutierrez</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>N</given-names></name></person-group>
<article-title>Synthesis and characterization of an N-acylsulfonamide inhibitor of human asparagine synthetase</article-title>. <source>Org Lett</source><year>2003</year>;<volume>5</volume>:<fpage>2033</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">12790521</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohashi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Oyama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyachi</surname><given-names>H</given-names></name></person-group>
<article-title>Different structures of the two peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist</article-title>. <source>Bioorg Med Chem Lett</source><year>2015</year>;<volume>25</volume>:<fpage>2639</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">25987371</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Lellis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Florio</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines</article-title>. <source>Chem Biol Drug Des</source><year>2017</year>;<volume>90</volume>:<fpage>1029</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">28544586</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal" id="CIT0013-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Sapegin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kalinin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Unprotected primary sulfonamide group facilitates ring-forming cascade en route to polycyclic [1,4]oxazepine-based carbonic anhydrase inhibitors</article-title>. <source>Bioorg Chem</source><year>2018</year>;<volume>76</volume>:<fpage>140</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">29175585</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0013-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2012</year>;<volume>27</volume>:<fpage>759</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">22468747</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0013-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Melis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>68</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">27775452</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal" id="CIT0014-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Petrou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Geronikaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Terzi</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Inhibition of carbonic anhydrase isoforms I, II, IX and XII with secondary sulfonamides incorporating benzothiazole scaffolds</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2016</year>;<volume>31</volume>:<fpage>1306</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26745009</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0014-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Gul</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Mete</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Taslimi</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Synthesis, carbonic anhydrase I and II inhibition studies of the 1,3,5-trisubstituted-pyrazolines</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>189</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">27774818</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal" id="CIT0015-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>D&#x02019;Ascenzio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guglielmi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>51</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27784170</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0015-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Pustenko</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stepanovs</surname><given-names>D</given-names></name>, <name name-style="western"><surname>&#x0017d;alubovskis</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>767</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">28537099</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alp</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Maresca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alp</surname><given-names>NA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2013</year>;<volume>28</volume>:<fpage>294</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22380772</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal" id="CIT0017-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D&#x02019;Ambrosio</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?</article-title><source>Chem Rev</source><year>2012</year>;<volume>112</volume>:<fpage>4421</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">22607219</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0017-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas</article-title>. <source>Expert Opin Ther Pat</source><year>2018</year>;<volume>28</volume>:<fpage>709</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30217119</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0017-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Krasavin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Korsakov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ronzhina</surname><given-names>O</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Primary mono- and bis-sulfonamides obtained via regiospecific sulfochlorination of N-arylpyrazoles: inhibition profile against a panel of human carbonic anhydrases</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>920</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28718328</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Atmaca</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Keskin</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II</article-title>. <source>Bioorg Med Chem</source><year>2015</year>;<volume>23</volume>:<fpage>2598</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">25863492</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal" id="CIT0019-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Awadallah</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mahmoud</surname><given-names>WR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Inhibition studies on a panel of human carbonic anhydrases with N1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2018</year>;<volume>33</volume>:<fpage>629</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">29536779</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0019-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Zengin Kurt</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sonmez</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Durdagi</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Synthesis, biological activity and multiscale molecular modeling studies for coumaryl-carboxamide derivatives as selective carbonic anhydrase IX inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>1042</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">28776440</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal" id="CIT0020-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Maresca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Carbonic anhydrase inhibitors: x-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II</article-title>. <source>Chem Commun (Camb)</source><year>2011</year>;<volume>47</volume>:<fpage>11636</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21952494</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0020-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Briganti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pierattelli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations</article-title>. <source>Eur J Med Chem</source><year>1996</year>;<volume>31</volume>:<fpage>1001</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giancristofaro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPAR&#x003b1; antagonists</article-title>. <source>Bioorg Med Chem Lett</source><year>2011</year>;<volume>21</volume>:<fpage>4869</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">21742490</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D'Angelo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giancristofaro</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPAR&#x003b1;</article-title>. <source>Eur J Med Chem</source><year>2012</year>;<volume>58</volume>:<fpage>317</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23137448</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giampietro</surname><given-names>L</given-names></name>, <name name-style="western"><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giancristofaro</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPAR&#x003b1; agonistic activity</article-title>. <source>Med Chem</source><year>2014</year>;<volume>10</volume>:<fpage>59</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">23432317</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#x02019;Ascenzio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Secci</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies</article-title>. <source>Bioorg Med Chem</source><year>2014</year>;<volume>22</volume>:<fpage>3982</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25027802</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Monte</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Secci</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives</article-title>. <source>Eur J Med Chem</source><year>2014</year>;<volume>84</volume>:<fpage>240</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25019479</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Labute</surname><given-names>P</given-names></name></person-group>
<article-title>Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures</article-title>. <source>Proteins</source><year>2009</year>;<volume>75</volume>:<fpage>187</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">18814299</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal" id="CIT0027-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Akdemir</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Monte</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Computational investigation of the selectivity of salen and tetrahydrosalen compounds towards the tumor-associated hCA XII isozyme</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2015</year>;<volume>30</volume>:<fpage>114</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24666302</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0027-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>G&#x000fc;zel-Akdemir</surname><given-names>&#x000d6;</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Demir</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Novel thiazolidinone-containing compounds, without the well-known sulphonamide zinc-binding group acting as human carbonic anhydrase IX inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2018</year>;<volume>33</volume>:<fpage>1299</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">30249139</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0027-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Ramya</surname><given-names>PVS</given-names></name>, <name name-style="western"><surname>Angapelly</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Discovery of curcumin inspired sulfonamide derivatives as a new class of carbonic anhydrase isoforms I, II, IX, and XII inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>1274</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28965419</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>De Lellis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>di Giacomo</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Effects of PPAR&#x003b1; inhibition in head and neck paraganglioma cells</article-title>. <source>PLoS One</source><year>2017</year>;<volume>12</volume>:<fpage>e0178995</fpage>.<pub-id pub-id-type="pmid">28594934</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benedetti</surname><given-names>E</given-names></name>, <name name-style="western"><surname>d'Angelo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>PPAR&#x003b1; antagonist AA452 triggers metabolic reprogramming and increases sensitivity to radiation therapy in human glioblastoma primary cells</article-title>. <source>J Cell Physiol</source><year>2017</year>;<volume>232</volume>:<fpage>1458</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">27736000</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carrieri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verginelli</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide Peroxisome Proliferator-Activated Receptors &#x003b1; antagonists</article-title>. <source>Eur J Med Chem</source><year>2016</year>;<volume>114</volume>:<fpage>191</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">26974385</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalifah</surname><given-names>RG</given-names></name></person-group>
<article-title>The carbon dioxide hydration activity of carbonic anhydrase. I. Stop flow kinetic studies on the native human isoenzymes B and C</article-title>. <source>J Biol Chem</source><year>1971</year>;<volume>246</volume>:<fpage>2561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">4994926</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mocan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Locatelli</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Bioactive isoflavones from Pueraria lobata root and starch: Different extraction techniques and carbonic anhydrase inhibition</article-title>. <source>Food Chem Toxicol</source><year>2018</year>;<volume>112</volume>:<fpage>441</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28807875</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal" id="CIT0033-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group><article-title>Advances in structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source><year>2017</year>;<volume>12</volume>:<fpage>61</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27783541</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0033-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group><article-title>Structure and function of carbonic anhydrases</article-title>. <source>Biochem J</source><year>2016</year>;<volume>473</volume>:<fpage>2023</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27407171</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0033-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source><year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0033-gen-5">(d) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Manole</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Designing of novel carbonic anhydrase inhibitors and activators</article-title>. <source>Curr Med Chem Cardiovasc Hematol Agents</source><year>2004</year>;<volume>2</volume>:<fpage>49</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">15328829</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0033-gen-6">(e) <person-group person-group-type="author"><name name-style="western"><surname>Akocak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lolak</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Discovery of novel 1,3-diaryltriazene sulfonamides as carbonic anhydrase I, II, VII, and IX inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2018</year>;<volume>33</volume>:<fpage>1575</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">30296852</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal" id="CIT0034-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title><source>J Enzyme Inhib Med Chem</source><year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0034-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Rehman</surname><given-names>SU</given-names></name>, <name name-style="western"><surname>Chohan</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Gulnaz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title><italic>In-vitro</italic> antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2005</year>;<volume>20</volume>:<fpage>333</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">16206827</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0034-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Clare</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase activators. 3: structure&#x02010;activity correlations for a series of isozyme II activators</article-title>. <source>J Pharm Sci</source><year>1994</year>;<volume>83</volume>:<fpage>768</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">9120804</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0034-gen-5">(d) <person-group person-group-type="author"><name name-style="western"><surname>Ozensoy Guler</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2016</year>;<volume>31</volume>:<fpage>689</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">26118417</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0034-gen-6">(e) <person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Langella</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>1002</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">28738704</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal" id="CIT0035-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity</article-title>. <source>Expert Opin Ther Pat</source><year>2003</year>;<volume>13</volume>:<fpage>1545</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0035-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Winum</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>El Cheikh</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue</article-title>. <source>J Med Chem</source><year>2006</year>;<volume>49</volume>:<fpage>7024</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">17125255</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0035-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Gul</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Mete</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Eren</surname><given-names>SE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group><article-title>Designing, synthesis and bioactivities of 4-[3-(4-hydroxyphenyl)-5-aryl-4,5-dihydro-pyrazol-1-yl]benzenesulfonamides</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>169</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">27774817</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0035-gen-5">(d) <person-group person-group-type="author"><name name-style="western"><surname>Alper T&#x000fc;rko&#x0011f;lu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>&#x0015e;ent&#x000fc;rk</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Ekinci</surname><given-names>D</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitory properties of some uracil derivatives</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2017</year>;<volume>32</volume>:<fpage>74</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28097897</pub-id></mixed-citation></ref></ref-list></back></article>